Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Quercetin  COVID-19 treatment studies for Quercetin  C19 studies: Quercetin  Quercetin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  

Oral Quercetin in Adult Patients as a Potential Nutraceutical against Coronavirus Disease 2019 (COVID-19)

Aguilar et al., Journal of Advances in Medical and Pharmaceutical Sciences, doi:10.9734/jamps/2021/v23i330222
Aguilar et al., Oral Quercetin in Adult Patients as a Potential Nutraceutical against Coronavirus Disease 2019 (COVID-19), Journal of Advances in Medical and Pharmaceutical Sciences, doi:10.9734/jamps/2021/v23i330222
Apr 2021   Source   PDF  
  All Studies   Meta
Prospective study of 52 patients treated with quercetin. There was no control group.
Aguilar et al., 8 Apr 2021, peer-reviewed, 3 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperQuercetinAll
Oral Quercetin in Adult Patients as a Potential Nutraceutical against Coronavirus Disease 2019 (COVID-19)
Juan Fernando Ibarra Aguilar, Gabriela Ariane Sanabria Báez, Fernando Galeano
Journal of Advances in Medical and Pharmaceutical Sciences, doi:10.9734/jamps/2021/v23i330222
Aim: To establishing the use of oral Quercetin as a potential nutraceutical against Coronavirus Disease 2019. Methods: A descriptive, prospective longitudinal study was carried out on 52 patients treated at the ECOMED-LAMB Clinic, in the period from the onset of Covid-19 in our country, March 3, 2020 to January 2021. Results: Were studied 52 patients COVID-19 positive, 20 (38.4%) were in preventive treatment and 32 patients (61.5%) was administered biological therapy once the diagnosis, no difference was found between female or male sex and the predominant age was those over 60 years. Twenty-four patients (70.6%) have presented at least one comorbidity. Original Research Article The association of hospitalization with preventive treatment was not significant (p=0.166), we observed difference in the evolution of the patients (p= 0.084). Conclusions: Quercetin could prevent and decrease the duration of SARSCoV plausible to propose the prophylactic use of this flavonoid in order to achieve clinical benefits.
COMPETING INTERESTS Authors have declared that no competing interests exist.
Andersen, Weber, Wood, Hughes, Murray et al., In-vitro virucidal activity of selected anthraquinones and anthraquinone derivatives, Antiviral Research
Badawi, Ryoo, Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis, International Journal of Infection Disease, doi:10.1016/j.ijid.2016.06.015
Biancatelli, Berrill, Catravas, Marik, Quercetin and vitamin C: An experimental, synergistic therapy for the prevention and treatment of SARSCoV-2 related disease (COVID-19), Frontiers in Immunology, doi:10.3389/fimmu.2020.01451
Booth, Matukas, Tomlinson, Rachlis, Rose et al., Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area, Journal of the American Medical Association, doi:10.1001/jama.289.21.JOC30885
Carr, Maggini, Immune Function, Nutrients, doi:10.3390/nu9111211
Chen, Liu, Liu, Liu, Xu et al., A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19
Dhyuti, Kumar, Alok, Ivermectin: Potential candidate for the treatment of COVID-19, Braz J Infect Dis, doi:10.1016/j.bjid.2020.06.002
Furuya, Uozaki, Yamasaki, Arakawa, Aritakoyama, Antiviral effects of ascorbic and dehydroascorbic acids in-vitro, International Journal of Molecular Medicine, doi:10.3892/ijmm_00000053
Ganesan, Faris, Comstock, Wang, Nanua et al., Quercetin inhibits rhinovirus replication in vitro and in-vivo, Antiviral Research, doi:10.1016/j.antiviral.2012.03.005
Gonzalez, Fontanes, Raychaudhuri, Loo, Loo et al., The heat shock protein inhibitor Quercetin attenuates hepatitis C virus production, Hepatology
Harwood, Danielewska-Nikiel, Borzelleca, Flamm, Williams et al., A critical review of the data related to the safety of quercetin and lack of evidence in vivo toxicity, including lack of genotoxic/carcinogenic properties, Food and Chemical Toxicology
Keller, Inventor, None
Kim, Jeon, Ko, Flavanone glycosides from Citrus junos and their antiinfluenza virus activity, Planta Medica
Li, Yao, Han, Yang, Chaudhry et al., Quercetin, inflammation and immunity, Nutrients, doi:10.3390/nu8030167
Moreira, Lima, Da Cruz, Quercetin as a potential nutraceutic against coronavirus disease 2019 (COVID-19), Ars Pharmaceutica, doi:10.30827/ars.v62i1.15684
Mrityunjaya, Pavithra, Neelam, Janhavi, Halami et al., Immune-boosting, antioxidant and antiinflammatory food supplements targeting pathogenesis of COVID-19
Olthof, Hollman, Vree, Katan, Bioavalabilities of quercetin-3-glucoside anda quercetin-4'-glucoside do not differ in humans, The Journal of Nutrition
Palamar, Gruzeva, The estimation of economic effectiveness of preventive measures of non-infectious diseases, Wiadomosci Lekarskie
Phoenix Biosciences, Assignee, Treatments for viral infections, United States Patent US
Semple, Pyke, Reynolds, Flower, In-vitro antiviral activity of the anthraquinone chrysophanic acid against poliovirus, Antiviral Res
Smith, Smith, Repurposing therapeutics for COVID-19: Supercomputer-based docking to the SARSCoV-2 viral spike protein and viral spike protein-human ACE2 interface, Chem Rxiv, doi:10.26434/chemrxiv.11871402
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, Journal of the American Medical Association, doi:10.1001/jama.2020.1585_________________________________________________________________________________
Wu, Li, Li, He, Jiang et al., Quercetin as an antiviral agent inhibits Influenza A Virus (IAV) entry, Viruses, doi:10.3390/v8010006
Yi, Li, Yuan, Qu, Chen et al., Small molecules block ingtheentry of severe acute respiratory syndrome coronavirus into host cells, Journal of Virology
Yi, Li, Yuan, Qu, Chen et al., Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells, Journal of Virology, doi:10.1128/JVI.78.20.11334-11339.2004
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: A retrospective cohort study, The Lancet, doi:10.1016/S0140-6736(20)30566-3
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop